Cited by 299T-cell and B-cell ImmunologyCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record; 196 of the 211 references it cites were found in a registry or an index.

Tumor-infiltrating T lymphocytes: friends or foes?

Open access

Yu, Ping, Fu, Yang-Xin·2006·Laboratory Investigation

Open this paper in CoChat — free account Open PDF

Abstract

The prognostic significance of tumor-infiltrating lymphocytes (TILs) has been a longstanding topic of debate. In cases where TILs have improved patient outcome, T lymphocytes are recognized as the main effectors of antitumor immune responses. However, recent studies have revealed that a subset of CD4(+) T cells, referred to as CD4(+)CD25(+) regulatory T cells (Treg), may accumulate in the tumor environment and suppress tumor-specific T-cell responses, thereby hindering tumor rejection. Hence, predicting tumor behavior on the basis of an indiscriminate evaluation of tumor-infiltrating T cells may result in inconsistent prognostic accuracy. The presence of infiltrating CD4(+)CD25(+) Treg may be detrimental to the host defense against the tumor, while the presence of effector T lymphocytes, including CD8(+) T cells and non-regulatory CD4(+) helper T cells may be beneficial. Enhanced recruitment of antitumor effector T lymphocytes to tumor tissue in addition to inhibition of local Treg, may therefore be an ideal target for improving cancer immunotherapy. This article reviews the antitumor functions of T-lymphocytes, with special attention given to CD4(+) regulatory T-cells within the tumor environment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/labinvest.3700389

Cites

196 of 196 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells
Park, J., Adoro, S., Guinter, T. I., Erman, B., Alag, A., Catálfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3
Chen, W., Jin, W., Hardegen, N. J., Lei, K.-J., Li, L., Marinos, N. J., McGrady, G., & Wahl, S. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030152 · Cited by 4,678
The expanding universe of T-cell subsets: Th1, Th2 and more
Mosmann, T. R., & Sad, S. (1996) · Immunology Today · doi:10.1016/0167-5699(96)80606-2 · Cited by 3,603
The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3
Bennett, C. L., Christie, J., Ramsdell, F., Brunkow, M., Ferguson, P., Whitesell, L., Kelly, T., Saulsbury, F., Chance, P., & Ochs, H. (2001) · Nature Genetics · doi:10.1038/83713 · Cited by 3,576
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
N aturally A rising CD4+R egulatory T C ells for I mmunologic S elf -T olerance and N egative C ontrol of I mmune R esponses
Sakaguchi, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,315
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,235
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,860
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
Dranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P. T., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. M., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,822
Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse
Brunkow, M. E., Jeffery, E. W., Hjerrild, K. A., Paeper, B. W., Clark, L. B., Yasayko, S.-A., Wilkinson, J. E., Galas, D. J., Ziegler, S. F., & Ramsdell, F. (2001) · Nature Genetics · doi:10.1038/83784 · Cited by 2,628
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
Ridge, J. P., Rosa, F. D., & Matzinger, P. (1998) · Nature · doi:10.1038/30989 · Cited by 2,360
CD4+CD25+ suppressor T cells: more questions than answers
Shevach, E. M. (2002) · Nature reviews. Immunology · doi:10.1038/nri821 · Cited by 2,097
Help for cytotoxic-T-cell responses is mediated by CD40 signalling
Bennett, S. R. M., Carbone, F., Karamalis, F., Flavell, R. A., Miller, J. F. A. P., & Heath, W. R. (1998) · Nature · doi:10.1038/30996 · Cited by 2,091
A Randomized Comparison of Antiplatelet and Anticoagulant Therapy after the Placement of Coronary-Artery Stents
Schömig, A., Neumann, F., Kastrati, A., Schühlen, H., Blasini, R., Hadamitzky, M., Walter, H., Zitzmann-Roth, E.-M., Richardt, G., Alt, E., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604253341702 · Cited by 2,016
Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation.
Cella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P. J. L., Lanzavecchia, A., & Alber, G. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.2.747 · Cited by 1,982
Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function
Zajac, A. J., Blattman, J. N., Murali-Krishna, K., Sourdive, D. J. D., Suresh, M., Altman, J. D., & Ahmed, R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2205 · Cited by 1,978
X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy
Wildin, R. S., Ramsdell, F., Peake, J., Faravelli, F., Casanova, J., Buist, N. R. M., Levy‐Lahad, E., Mazzella, M., Goulet, O., Perroni, L., et al. (2001) · Nature Genetics · doi:10.1038/83707 · Cited by 1,916
CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity
Belkaid, Y., Piccirillo, C. A., Méndez, S., Shevach, E. M., & Sacks, D. L. (2002) · Nature · doi:10.1038/nature01152 · Cited by 1,726
Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming
Wolfers, J., Lozier, A., Raposo, G., Régnault, A., Théry, C., Masurier, C., Flament, C., Pouzieux, S., Faure, F., Tursz, T., et al. (2001) · Nature Medicine · doi:10.1038/85438 · Cited by 1,643
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., & Schoenberger, S. P. (2003) · Nature · doi:10.1038/nature01441 · Cited by 1,635
Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance
Sakaguchi, S., Sakaguchi, N., Shimizu, J., Yamazaki, S., Sakihama, T., Itoh, M., Kuniyasu, Y., Nomura, T., Toda, M., & Takahashi, T. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820102.x · Cited by 1,505
Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity
Shimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491
Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma
Liyanage, U. K., Moore, T. T., Joo, H., Tanaka, Y., Herrmann, V. M., Doherty, G. M., Drebin, J. A., Strasberg, S. M., Eberlein, T. J., Goedegebuure, P. S., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.5.2756 · Cited by 1,466
Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory
Shedlock, D. J., & Shen, H. (2003) · Science · doi:10.1126/science.1082305 · Cited by 1,450
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
Regulatory T cells in transplantation tolerance
Wood, K. J., & Sakaguchi, S. (2003) · Nature reviews. Immunology · doi:10.1038/nri1027 · Cited by 1,319
Progress in human tumour immunology and immunotherapy
Rosenberg, S. A. (2001) · Nature · doi:10.1038/35077246 · Cited by 1,317
Model Predicting Survival in Stage I Melanoma Based on Tumor Progression
Clark, W. H., Elder, D. E., Guerry, D., Braitman, L. E., Trock, B. J., Schultz, D., Synnestvedt, M. B., & Halpern, A. C. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.24.1893 · Cited by 1,247
Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25– T cells
Walker, M., Kasprowicz, D. J., Gersuk, V. H., Bénard, A., Landeghen, M. V., Buckner, J. H., & Ziegler, S. F. (2003) · Journal of Clinical Investigation · doi:10.1172/jci19441 · Cited by 1,242
Immunity to Methylcholanthrene-Induced Sarcomas
Prehn, R. T., & Main, J. M. (1957) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/18.6.769 · Cited by 1,230
Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help
Sun, J. C., & Bevan, M. J. (2003) · Science · doi:10.1126/science.1083317 · Cited by 1,213
CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.
Naito, Y., Saito, K., Shiiba, K., Ohuchi, A., Saigenji, K., Nagura, H., & Ohtani, H. (1998) · PubMed · Cited by 1,193
Regulatory T cells in the control of immune pathology
Maloy, K. J., & Powrie, F. M. (2001) · Nature Immunology · doi:10.1038/ni0901-816 · Cited by 1,177
CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection
Matloubian, M., Concepcion, R. J., & Ahmed, R. (1994) · Journal of Virology · doi:10.1128/jvi.68.12.8056-8063.1994 · Cited by 1,162
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y.-C., Golumbek, P. T., Ahmadzadeh, M., Jaffee, E. M., Pardoll, D. M., & Levitsky, H. I. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,159
Ex Vivo Isolation and Characterization of Cd4+Cd25+ T Cells with Regulatory Properties from Human Blood
Dieckmann, D., Ploettner, H., Berchtold, S., Berger, T. G., & Schuler, G. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.11.1303 · Cited by 1,140
Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
Woo, E. Y., Chu, C., Goletz, T. J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S. C., Kaiser, L. R., & June, C. H. (2001) · PubMed · Cited by 1,113
The Th1/Th2 paradigm
Romagnani, S. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)80019-9 · Cited by 1,072
Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.
Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., & Nakayama, E. (1999) · PubMed · Cited by 1,062
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses
Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008
Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.
Lin, K. Y., Guarnieri, F., Staveley-O’Carroll, K. F., Levitsky, H. I., August, J. T., Pardoll, D. M., & Wu, T. ‐. (1996) · PubMed · Cited by 1,003
Abrogation of TGFβ Signaling in T Cells Leads to Spontaneous T Cell Differentiation and Autoimmune Disease
Gorelik, L., & Flavell, R. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80170-3 · Cited by 959
High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10.
Koch, F., Stanzl, U., Jennewein, P., Janke, K., Heufler, C., Kämpgen, E., Romani, N., & Schuler, G. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.2.741 · Cited by 928
Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response
Fearon, E. R., Pardoll, D. M., Itaya, T., Golumbek, P. T., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B., & Frost, P. (1990) · Cell · doi:10.1016/0092-8674(90)90591-2 · Cited by 916
Human tumor antigens recognized by T lymphocytes.
Boon, T., & van der Bruggen, P. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.3.725 · Cited by 855
Origin of regulatory T cells with known specificity for antigen
Apostolou, I., Sarukhan, A., Klein, L., & von Boehmer, H. (2002) · Nature Immunology · doi:10.1038/ni816 · Cited by 847
Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
Zitvogel, L., Mayordomo, J. I., Tjandrawan, T., DeLeo, A. B., Clarke, M. R., Lotze, M. T., & Storkus, W. J. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.1.87 · Cited by 824
Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells
Feltkamp, M. C. W., Smits, H. L., Vierboom, M., Minnaar, R., de Jongh, B. M., Drijfhout, J. W., ter Schegget, J., Melief, C. J. M., & Kast, W. M. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230929 · Cited by 821
Helping the CD8+ T-cell response
Bevan, M. J. (2004) · Nature reviews. Immunology · doi:10.1038/nri1413 · Cited by 790
Murine interleukin-4 displays potent anti-tumor activity in vivo
Tepper, R. I., Pattengale, P. K., & Leder, P. (1989) · Cell · doi:10.1016/0092-8674(89)90925-2 · Cited by 777
Does the Immune System See Tumors as Foreign or Self?
Pardoll, D. M. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141135 · Cited by 770
LIGHT, a New Member of the TNF Superfamily, and Lymphotoxin α Are Ligands for Herpesvirus Entry Mediator
Mauri, D. N., Ebner, R., Montgomery, R. I., Kochel, K. D., Cheung, T. C., Yu, G.-L., Ruben, S. M., Murphy, M., Eisenberg, R. J., Cohen, G. H., et al. (1998) · Immunity · doi:10.1016/s1074-7613(00)80455-0 · Cited by 757
Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host.
Klein, G., Sjögren, H. O., Klein, E., & Hellström, K. E. (1960) · PubMed · Cited by 742
Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments
Ahmad‐Nejad, P., Häcker, H., Rutz, M., Bauer, S., Vabulas, R. M., & Wagner, H. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200207)32:7 · Cited by 728
Self-citation
Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease.
Sakaguchi, S., Fukuma, K., Kuribayashi, K., & Masuda, T. (1985) · The Journal of Experimental Medicine · doi:10.1084/jem.161.1.72 · Cited by 728
Induction of a CD8+ Cytotoxic T Lymphocyte Response by Cross-priming Requires Cognate CD4+ T Cell Help
Bennett, S. R. M., Carbone, F., Karamalis, F., Miller, J. F. A. P., & Heath, W. R. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.1.65 · Cited by 725
Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4
Golumbek, P. T., Lazenby, A. J., Levitsky, H. I., Jaffee, L., Karasuyama, H., Baker, M., & Pardoll, D. M. (1991) · Science · doi:10.1126/science.1948050 · Cited by 719
Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation
Woo, E. Y., Yeh, H., Chu, C., Schlienger, K., Carroll, R. G., Riley, J. L., Kaiser, L. R., & June, C. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4272 · Cited by 689
Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin.
Ej, F. (1953) · PubMed · Cited by 687
The role of CD4+ T cell responses in antitumor immunity
Pardoll, D. M., & Topalian, S. L. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80228-8 · Cited by 672
Adoptive-cell-transfer therapy for the treatment of patients with cancer
Dudley, M. E., & Rosenberg, S. A. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1167 · Cited by 653
CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection
Sun, J. C.-Y., Williams, M. A., & Bevan, M. J. (2004) · Nature Immunology · doi:10.1038/ni1105 · Cited by 644
Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity.
Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., Suzuki, Y., Shintaku, I., Nagura, H., & Ohtani, H. (2001) · PubMed · Cited by 639
DEVELOPMENT AND MATURATION OF SECONDARY LYMPHOID TISSUES
Fu, Y., & Chaplin, D. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.399 · Cited by 615
Self-citation
A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens
Rosenberg, S. A. (1999) · Immunity · doi:10.1016/s1074-7613(00)80028-x · Cited by 565
Lymphotoxin α/β and Tumor Necrosis Factor Are Required for Stromal Cell Expression of Homing Chemokines in B and T Cell Areas of the Spleen
Ngo, V. N., Körner, H., Gunn, M. D., Schmidt, K. N., Riminton, S., Cooper, M. D., Browning, J. L., Sedgwick, J. D., & Cyster, J. G. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.2.403 · Cited by 552
Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis
Rongvaux, A., Shea, R. J., Mulks, M. H., Gigot, D., Urbain, J., Léo, O., & Andris, F. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200211)32:11 · Cited by 551
Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells
Turk, M. J., Guevara-Patino, J. A., Rizzuto, G. A., Engelhorn, M. E., & Houghton, A. N. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041130 · Cited by 537
IL-10–producing and naturally occurring CD4+ Tregs: limiting collateral damage
O’Garra, A., Vieira, P. L., Vieira, P., & Goldfeld, A. E. (2004) · Journal of Clinical Investigation · doi:10.1172/jci23215 · Cited by 530
Tumor-Specific Human CD4+ Regulatory T Cells and Their Ligands
Wang, H. Y., Lee, D. A., Peng, G., Guo, Z., Li, Y., Kiniwa, Y., Shevach, E. M., & Wang, R. (2004) · Immunity · doi:10.1016/s1074-7613(03)00359-5 · Cited by 515
Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma
Marshall, N. A., Christie, L. E., Munro, L., Culligan, D. J., Johnston, P. W., Barker, R. N., & Vickers, M. A. (2003) · Blood · doi:10.1182/blood-2003-07-2594 · Cited by 506
Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas.
Schumacher, K., Haensch, W., Röefzaad, C., & Schlag, P. M. (2001) · PubMed · Cited by 503
Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells.
Cardin, R. D., Brooks, J. W., Sarawar, S. R., & Doherty, P. C. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.3.863 · Cited by 501
CD4 + CD25 + regulatory T cells in patients with gastrointestinal malignancies
Sasada, T., Kimura, M., Yoshida, Y., Kanai, M., & Takabayashi, A. (2003) · Cancer · doi:10.1002/cncr.11618 · Cited by 485
Antigenicity of Murine Skin Tumors Induced by Ultraviolet Light2
Kripke, M. L. (1974) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/53.5.1333 · Cited by 481
Distinct Role of Antigen-Specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication in Vivo
Nishimura, T., Iwakabe, K., Sekimoto, M., Ohmi, Y., Yahata, T., Nakui, M., Sato, T., Habu, S., Tashiro, H., Sato, M. M., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.5.617 · Cited by 468
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
Machiels, J.-P., Reilly, R. T., Emens, L. A., Ercolini, A. M., Lei, R. Y., Weintraub, D., Okoye, F. I., & Jaffee, E. M. (2001) · PubMed · Cited by 455
Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
Fields, R. C., Shimizu, K., & Mulé, J. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9482 · Cited by 455
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors
Yu, P., Lee, Y., Liu, W., Krausz, T. N., Chong, A. S., Schreiber, H. W., & Fu, Y. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041684 · Cited by 441
Self-citation
Regulatory T cells under scrutiny
Bach, J. F. (2003) · Nature reviews. Immunology · doi:10.1038/nri1026 · Cited by 414
CD4 + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ
Mumberg, D., Monach, P. A., Wanderling, S. S., Philip, M., Toledano, A. Y., Schreiber, R. D., & Schreiber, H. W. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8633 · Cited by 385
Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes
Cosmi, L., Liotta, F., Lazzeri, E., Francalanci, M., Angeli, R., Mazzinghi, B., Santarlasci, V., Manetti, R., Vanini, V., Romagnani, P., et al. (2003) · Blood · doi:10.1182/blood-2003-04-1320 · Cited by 382
Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.
Porgador, A., & Gilboa, E. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.182.1.255 · Cited by 373
T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor.
Berendt, M. J., & North, R. J. (1980) · The Journal of Experimental Medicine · doi:10.1084/jem.151.1.69 · Cited by 370
Intradermal Immunization of C3H Mice against a Sarcoma That Originated in an Animal of the Same Line
Gross, L. (1943) · Cancer Research · Cited by 362
Priming of naive T cells inside tumors leads to eradication of established tumors
Yu, P., Lee, Y., Liu, W., Chin, R., Wang, J. H., Wang, Y., Schietinger, A., Philip, M., Schreiber, H. W., & Fu, Y. (2004) · Nature Immunology · doi:10.1038/ni1029 · Cited by 354
Self-citation
Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice
Battegay, M., Moskophidis, D., Rahemtulla, A., Hengartner, H., Mak, T. W., & Zinkernagel, R. M. (1994) · Journal of Virology · doi:10.1128/jvi.68.7.4700-4704.1994 · Cited by 320
Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes.
Greenberg, P. D., Cheever, M. A., & Fefer, A. (1981) · The Journal of Experimental Medicine · doi:10.1084/jem.154.3.952 · Cited by 309
Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic Study
Spriggs, D. R., Sherman, M. L., MICHIE, H. R., Arthur, K. A., Imamura, K., Wilmore, D. W., Frei, E., & Kufe, D. W. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.13.1039 · Cited by 309
Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes
Kast, W. M., Offringa, R., Peters, P. J., Voordouw, A. C., Meloen, R. H., van der Eb, A. J., & Melief, C. J. M. (1989) · Cell · doi:10.1016/0092-8674(89)90006-8 · Cited by 301
Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway
Tamada, K., Shimozaki, K., Chapoval, A. I., Zhu, G., Sica, G., Flies, D. B., Boone, T., Hsu, H., Fu, Y., Nagata, S., et al. (2000) · Nature Medicine · doi:10.1038/73136 · Cited by 300
Self-citation
Regulatory T Cells in the Control of Autoimmunity: the Essential Role of Transforming Growth Factor β and Interleukin 4 in the Prevention of Autoimmune Thyroiditis in Rats by Peripheral CD4+CD45RC− Cells and CD4+CD8− Thymocytes
Seddon, B., & Mason, D. (1999) · Journal of Experimental Medicine · doi:10.1084/jem.189.2.279 · Cited by 294
LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer.
Zhai, Y., Guo, R., Hsu, T.-L., Yu, G., Ni, J., Kwon, B. S., Jiang, W. G., Lu, J., Tan, J., Ugustus, M., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3492 · Cited by 270
Role of Dendritic Cell Targeting in Venezuelan Equine Encephalitis Virus Pathogenesis
MacDonald, G. H., & Johnston, R. E. (2000) · Journal of Virology · doi:10.1128/jvi.74.2.914-922.2000 · Cited by 266
Identification of a CD4 binding site on the β2 domain of HLA-DR molecules
Cammarota, G., Scheirle, A., Takács, B., Doran, D. M., Knorr, R., Bannwarth, W., Guardiola, J., & Sinigaglia, F. (1992) · Nature · doi:10.1038/356799a0 · Cited by 266
Regulation of Peripheral Lymph Node Genesis by the Tumor Necrosis Factor Family Member Trance
Kim, D., Mebius, R. E., MacMicking, J. D., Jung, S., Cupedo, T., Castellanos, Y. P., Rho, J., Wong, B. R., Josien, R., Kim, N., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.10.1467 · Cited by 264
Alloantigen specific CD8+CD28− FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity
Manavalan, J. S., Kim‐Schulze, S., Scotto, L., Naiyer, A. J., Vlad, G., Colombo, P. C., Marboe, C. C., MANCINI, D. M., Cortesini, R., & Suciu‐Foca, N. (2004) · International Immunology · doi:10.1093/intimm/dxh107 · Cited by 256
Interleukin 7 induces CD4+ T cell-dependent tumor rejection.
Hock, H. R., Dorsch, M., Diamantstein, T., & Blankenstein, T. J. F. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.174.6.1291 · Cited by 247
A unique tumor antigen produced by a single amino acid substitution
Monach, P. A., Meredith, S. C., Siegel, C., & Schreiber, H. W. (1995) · Immunity · doi:10.1016/1074-7613(95)90078-0 · Cited by 242
T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures.
Knuth, A., Danowski, B., Oettgen, H. F., & Old, L. J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.11.3511 · Cited by 236
Increasing Tumor Antigen Expression Overcomes “Ignorance” to Solid Tumors via Crosspresentation by Bone Marrow-Derived Stromal Cells
Spiotto, M. T., Yu, P., Rowley, D. A., Nishimura, M. I., Meredith, S. C., Gajewski, T. F., Fu, Y., & Schreiber, H. W. (2002) · Immunity · doi:10.1016/s1074-7613(02)00480-6 · Cited by 234
Self-citation
Proteolysis and class I major histocompatibility complex antigen presentation
York, I. A., Goldberg, A. L., Mo, X. Y., & Rock, K. L. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01355.x · Cited by 232
CD4+ regulatory T cells in autoimmunity and allergy
de Lafaille, M. A. C., & Lafaille, J. J. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00408-9 · Cited by 230
Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses
Shi, Y., Zheng, W., & Rock, K. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.260497597 · Cited by 226
The Lymphotoxin-β Receptor Is Necessary and Sufficient for LIGHT-mediated Apoptosis of Tumor Cells
Rooney, I. A., Butrovich, K. D., Glass, A. A., Borboroglu, S., Benedict, C. A., Whitbeck, J. C., Cohen, G. H., Eisenberg, R. J., & Ware, C. F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.19.14307 · Cited by 225
In Vivo Cross-Priming of MHC Class I–Restricted Antigens Requires the TAP Transporter
Huang, A. Y.-C., Bruce, A. T., Pardoll, D. M., & Levitsky, H. I. (1996) · Immunity · doi:10.1016/s1074-7613(00)80248-4 · Cited by 224
Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma.
Steitz, J., Brück, J., Lenz, J., Knop, J., & Tüting, T. (2001) · PubMed · Cited by 214
Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma.
Noguchi, Y., Richards, E. C., Chen, Y., & Old, L. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.6.2219 · Cited by 212
Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice.
Jones, E., Dahm‐Vicker, M., Simon, A. K., Green, A., Powrie, F. M., Cerundolo, V., & Gallimore, A. (2002) · PubMed · Cited by 208
Dendritic cells require maturation via CD40 to generate protective antitumor immunity.
Mackey, M. F., Gunn, J. R., Maliszewski, C. R., Kikutani, H., Noelle, R. J., & Barth, R. J. (1998) · PubMed · Cited by 201
Cd40-Independent Pathways of T Cell Help for Priming of Cd8+ Cytotoxic T Lymphocytes
Lu, Z., Yuan, L., Zhou, X., Sotomayor, E. M., Levitsky, H. I., & Pardoll, D. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.3.541 · Cited by 196
IFN-γ-Dependent Inhibition of Tumor Angiogenesis by Tumor-Infiltrating CD4+ T Cells Requires Tumor Responsiveness to IFN-γ
Beatty, G. L., & Paterson, Y. Y. W. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2276 · Cited by 195
CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination
Casares, N., Arribillaga, L., Sarobe, P., Dotor, J., de Cerio, A. L.-D., Melero, I., Prìeto, J., Borrás‐Cuesta, F., & Lasarte, J. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.5931 · Cited by 194
Targeting of Lymphotoxin-α to the Tumor Elicits an Efficient Immune Response Associated with Induction of Peripheral Lymphoid-like Tissue
Schrama, D., Straten, P. T., Fischer, W. H., McLellan, A. D., Bröcker, E., Reisfeld, R. A., & Becker, J. C. (2001) · Immunity · doi:10.1016/s1074-7613(01)00094-2 · Cited by 192
Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy
Wick, M., Dubey, P., Koeppen, H., Siegel, C., Fields, P. E., Chen, L., Bluestone, J. A., & Schreiber, H. W. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.2.229 · Cited by 191
Disregulation in TH1 and TH2 subsets of CD4 + T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression
Pellegrini, P., Berghella, A. M., Beato, T. D., Cicia, S., Adorno, D., & Casciani, C. U. (1996) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050244 · Cited by 190
Substitution at residue 227 of H–2 class I molecules abrogates recognition by CD8-dependent, but not CD8-independent, cytotoxic T lymphocytes
Potter, T. A., Rajan, T. V., Dick, R. F., & Bluestone, J. A. (1989) · Nature · doi:10.1038/337073a0 · Cited by 189
In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression.
Levitsky, H. I., Lazenby, A., Hayashi, R. J., & Pardoll, D. M. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.179.4.1215 · Cited by 188
IL-12 induces T helper 1-directed antitumor response
Tsung, K., Meko, J. B., Peplinski, G. R., Tsung, Y. L., & Norton, J. A. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.7.3359 · Cited by 184
Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene
Cavallo, F., Giovarelli, M., Gulino, A., Vacca, A., Stoppacciaro, A., Modesti, A., & Forni, G. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.11.3627 · Cited by 180
Immune Enhancement of Skin Carcinogenesis by CD4+ T Cells
Daniel, D., Meyer-Morse, N., Bergsland, E. K., Dehne, K., Coussens, L. M., & Hanahan, D. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021047 · Cited by 180
T-regulatory 1 cells: A novel subset of CD4+ T cells with immunoregulatory properties
Levings, M. K., & Roncarolo, M. (2000) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2000.106635 · Cited by 176
A Pathogenic Role of Th2 Cells and Their Cytokine Products on the Pulmonary Metastasis of Murine B16 Melanoma
Kobayashi, M., Kobayashi, H., Pollard, R. B., & Suzuki, F. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.12.5869 · Cited by 171
Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants.
Allione, A., Consalvo, M., Nanni, P., Lollini, P., Cavallo, F., Giovarelli, M., Forni, M., Gulino, A., Colombo, M. P., & Dellabona, P. (1994) · PubMed · Cited by 162
Cutting Edge: Dendritic Cells Require Maturation via CD40 to Generate Protective Antitumor Immunity
Mackey, M. F., Gunn, J. R., Maliszewski, C. R., Kikutani, H., Noelle, R. J., & Barth, R. J. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.5.2094 · Cited by 161
The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
Fujiwara, H., Fukuzawa, M., Yoshioka, T., Nakajima, H., & Hamaoka, T. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.3.1671 · Cited by 158
Regulatory T cells in spontaneous autoimmune encephalomyelitis
Furtado, G. D. C., Olivares–Villagómez, D., de Lafaille, M. A. C., Wensky, A. K., Latkowski, J.-A. M., & Lafaille, J. J. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820110.x · Cited by 155
The Requirement of Membrane Lymphotoxin for the Presence of Dendritic Cells in Lymphoid Tissues
Wu, Q., Wang, Y., Wang, J. H., Hedgeman, E. O., Browning, J. L., & Fu, Y. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.5.629 · Cited by 154
Self-citation
Gene-Modified Tumor Vaccine with Therapeutic Potential Shifts Tumor-Specific T Cell Response from a Type 2 to a Type 1 Cytokine Profile
Hu, H., Urba, W. J., & Fox, B. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.3033 · Cited by 153
Cutting Edge: STAT6-Deficient Mice Have Enhanced Tumor Immunity to Primary and Metastatic Mammary Carcinoma
Ostrand‐Rosenberg, S., Grusby, M. J., & Clements, V. K. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6015 · Cited by 143
Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infection. Protection by T cells is MHC-restricted and MHC-regulated; a model for MHC-disease associations.
Kast, W. M., Bronkhorst, A. M., de Waal, L. P., & Melief, C. J. M. (1986) · The Journal of Experimental Medicine · doi:10.1084/jem.164.3.723 · Cited by 140
Clonal analysis of cytotoxic T cell response against human melanoma.
Mukherji, B., & MacAlister, T. J. (1983) · The Journal of Experimental Medicine · doi:10.1084/jem.158.1.240 · Cited by 137
Tumor immunotherapy: the tumor cell as an antigen-presenting cell
Ostrand‐Rosenberg, S. (1994) · Current Opinion in Immunology · doi:10.1016/0952-7915(94)90075-2 · Cited by 130
Progress in the development of immunotherapy for the treatment of patients with cancer
Rosenberg, S. A. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00911.x · Cited by 124
Immunity to Methylcholanthrene-Induced Tumours in Inbred Rats Following Atrophy and Regression of the Implanted Tumours
Baldwin, R. W. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.70 · Cited by 123
Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma
Straume, O., & Akslen, L. A. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971021)74:5 · Cited by 123
T Helper 1 Cytokine mRNA Is Increased in Spontaneously Regressing Primary Melanomas
Lowes, M. A., Bishop, G. A., Crotty, K. A., Barnetson, R. S. C., & Halliday, G. M. (1997) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12292705 · Cited by 122
IFN-γ Can Promote Tumor Evasion of the Immune System In Vivo by Down-Regulating Cellular Levels of an Endogenous Tumor Antigen
Beatty, G. L., & Paterson, Y. Y. W. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5502 · Cited by 119
Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role
Aruga, A., Aruga, E., Tanigawa, K., Bishop, D. K., Sondak, V. K., & Chang, A. E. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.2.664 · Cited by 117
Divergent Roles for CD4+ T Cells in the Priming and Effector/Memory Phases of Adoptive Immunotherapy
Hu, H., Winter, H., Urba, W. J., & Fox, B. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.8.4246 · Cited by 114
Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity.
Awwad, M., & North, R. J. (1988) · The Journal of Experimental Medicine · doi:10.1084/jem.168.6.2193 · Cited by 111
SOME FURTHER DATA ON CYTOTOXIC ISOANTIBODIES IN THE MOUSE*
Boyse, E. A., Old, L. J., & Stockert, E. (1962) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1962.tb45339.x · Cited by 109
Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154.
Mackey, M., Gunn, J. R., Ting, P. P., Kikutani, H., Dranoff, G., Noelle, R. J., & Barth, R. J. (1997) · PubMed · Cited by 107
Cell‐mediated reaction against tumors induced by oncornaviruses. I. Kinetics and specificity of the immune response in Murine sarcoma virus (MSV)‐induced tumors and transplanted lymphomas
Leclerc, J. C., GOMARD, E., & Lévy, J. P. (1972) · International Journal of Cancer · doi:10.1002/ijc.2910100318 · Cited by 107
Reciprocal Changes in Tumor Antigenicity and Antigen-specific T Cell Function during Tumor Progression
Zhou, G., Lu, Z., McCadden, J., Levitsky, H. I., & Marson, A. L. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041240 · Cited by 107
Antigenic Specificity of Benzo[a]pyrene-Induced Sarcomas2
Globerson, A., & Feldman, M. M. (1964) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/32.6.1229 · Cited by 106
Cutting Edge: Differentiation of Antitumor CTL In Vivo Requires Host Expression of Stat1
Fallarino, F., & Gajewski, T. F. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.8.4109 · Cited by 106
Immunophenotypic characterization of Epstein-Barr virus-associated gastric carcinoma: massive infiltration by proliferating CD8+ T-lymphocytes.
Saiki, Y., Ohtani, H., Naito, Y., Miyazawa, M., & Nagura, H. (1996) · PubMed · Cited by 106
Virus-specific CD8 + T cell numbers are maintained during γ-herpesvirus reactivation in CD4-deficient mice
Stevenson, P. G., Belz, G. T., Altman, J. D., & Doherty, P. C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15565 · Cited by 100
Long-lasting CD8 T cell memory in the absence of CD4 T cells or B cells.
Rosa, F. D., & Matzinger, P. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.5.2153 · Cited by 98
CD40L is important for induction of, but not response to, costimulatory activity. ICAM-1 as the second costimulatory molecule rapidly up-regulated by CD40L
Shinde, S. S., Wu, Y. P., Guo, Y., Niu, Q., Xu, J., Grewal, I. S., Flavell, R. A., & Liu, Y. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.7.2764 · Cited by 97
What is the role of regulatory T cells in transplantation tolerance?
Zhai, Y., & Kupiec-Weglinski, J. W. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)00007-2 · Cited by 96
Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells.
Cheever, M. A., Thompson, D. B., Klarnet, J. P., & Greenberg, P. D. (1986) · The Journal of Experimental Medicine · doi:10.1084/jem.163.5.1100 · Cited by 95
Peptide loading of empty major histocompatibility complex molecules on RMA‐S cells allows the induction of primary cytotoxic T lymphocyte responses
Bruijn, M. L. H. D., Schumacher, T. N., Nieland, J. D., Ploegh, H. L., Kast, W. M., & Melief, C. J. M. (1991) · European Journal of Immunology · doi:10.1002/eji.1830211210 · Cited by 93
Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine.
Pan, Z. K., Ikonomidis, G., Pardoll, D. M., & Paterson, Y. Y. W. (1995) · PubMed · Cited by 93
Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity.
Bursuker, I., & North, R. J. (1984) · The Journal of Experimental Medicine · doi:10.1084/jem.159.5.1312 · Cited by 88
Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance.
Ward, P. L., Koeppen, H., Hurteau, T., Rowley, D. A., & Schreiber, H. W. (1990) · PubMed · Cited by 87
Spontaneous Rejection of Poorly Immunogenic P1.HTR Tumors by Stat6-Deficient Mice
Kacha, A. K., Fallarino, F., Markiewicz, M. A., & Gajewski, T. F. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6024 · Cited by 86
Protective antitumor immunity induced by immunization with completely allogeneic tumor cells.
Toes, R. E. M., Blom, R. J. J., van der Voort, E., Offringa, R., Melief, C. J. M., & Kast, W. M. (1996) · PubMed · Cited by 86
Th1 and Th2 Cell Clones to a Poorly Immunogenic Tumor Antigen Initiate CD8+ T Cell-Dependent Tumor Eradication In Vivo
Fallarino, F., Grohmann, U., Bianchi, R., Vacca, C., Fioretti, M. C., & Puccetti, P. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5495 · Cited by 85
The Critical Role of LIGHT, a TNF Family Member, in T Cell Development
Wang, J. H., Chun, T., Lo, J. C., Wu, Q., Wang, Y., Foster, A., Roca, K., Chen, M., Tamada, K., Chen, L., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.9.5099 · Cited by 75
Self-citation
Complementary Role of CD4+ T Cells and Secondary Lymphoid Tissues for Cross-presentation of Tumor Antigen to CD8+ T Cells
Yu, P., Spiotto, M. T., Lee, Y., Schreiber, H. W., & Fu, Y. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021804 · Cited by 75
Self-citation
Autoimmune thyroiditis induced in mice depleted of particular T cell subsets. I. Requirement of Lyt-1 dull L3T4 bright normal T cells for the induction of thyroiditis.
Sugihara, S., Izumi, Y., Yoshioka, T., Yagi, H., Tsujimura, T., Tarutani, O., Kohno, Y., Murakami, S., Hamaoka, T., & Fujiwara, H. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.1.105 · Cited by 72
Redundancy of Direct Priming and Cross-Priming in Tumor-Specific CD8+ T Cell Responses
Wolkers, M. C., Stoetter, G., Vyth‐Dreese, F. A., & Schumacher, T. N. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.7.3577 · Cited by 72
Retrovirally Transduced Mouse Dendritic Cells Require CD4+ T Cell Help to Elicit Antitumor Immunity: Implications for the Clinical Use of Dendritic Cells
Schnell, S., Young, J. W., Houghton, A. N., & Sadelain, M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.3.1243 · Cited by 67
Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity
Tüting, T., Steitz, J., Brück, J., Gambotto, A. A., Steinbrink, K., DeLeo, A. B., Robbins, P. D., Knop, J., & Enk, A. (1999) · The Journal of Gene Medicine · doi:10.1002/(sici)1521-2254(199911/12)1:6 · Cited by 66
Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
Li, J., Hu, P., Khawli, L. A., & Epstein, A. L. (2003) · PubMed · Cited by 66
Cancer mortality at very old ages
Smith, D. W. E. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7 · Cited by 61
Enhanced Growth of Primary Tumors in Cancer-Prone Mice after Immunization against the Mutant Region of an Inherited Oncoprotein
Siegel, C., Schreiber, K., Meredith, S. C., Beck‐Engeser, G., Lancki, D. W., Lazarski, C. A., Fu, Y., Rowley, D. A., & Schreiber, H. W. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.191.11.1945 · Cited by 59
Self-citation
Flow cytometric analysis of tumour‐infiltrating lymphocytes in patients with renal cell carcinoma
Kowalczyk, D. W., Skorupski, W., Kwias, Z., & Nowak, J. (1997) · British Journal of Urology · doi:10.1046/j.1464-410x.1997.00408.x · Cited by 56
Anti-θ Serum-indueed Suppression of the Cellular Transfer of Tumour-specific Immunity to a Syngeneic Plasma Cell Tumour
Rouse, B. T., Röllinghoff, M., & Warner, N. L. (1972) · Nature New Biology · doi:10.1038/newbio238116a0 · Cited by 56
Requirement of thymus-derived theta-positive lymphocytes for rejection of DNA virus (SV 40) tumors in mice.
Tevethia, S. S., Blasecki, J. W., Waneck, G. L., & Goldstein, A. L. (1974) · PubMed · Cited by 53
The relationships among tumor-infiltrating lymphocytes, histopathologic findings, and long-term clinical follow-up in renal cell carcinoma.
Kolbeck, P. C., Kaveggia, F. F., Johansson, S. L., Grune, M. T., & Taylor, R. J. (1992) · PubMed · Cited by 50
Separation and Characteristics of Tumor-Infiltrating Lymphocytes in Man
Klein, E., Vánky, F. B., Galili, U., Vose, B. M., & Fopp, M. (1980) · Springer eBooks · doi:10.1007/978-1-4684-3677-8_4 · Cited by 46
Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism.
Pulaski, B. A., McAdam, A. J., Hutter, E. K., Biggar, S., Lord, E. M., & Frelinger, J. G. (1993) · PubMed · Cited by 46
Point Mutation in Essential Genes with Loss or Mutation of the Second Allele
Beck‐Engeser, G., Monach, P. A., Mumberg, D., Yang, F. E., Wanderling, S. S., Schreiber, K., Espinosa, R., Beau, M. M. L., Meredith, S. C., & Schreiber, H. W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.3.285 · Cited by 46
The role of tumor-specific Lyt-1+2? T cells in eradicating tumor cells in vivo
Yoshioka, T., Fujiwara, H., Takai, Y., Ogata, M., Shimizu, J., & Hamaoka, T. (1987) · Cancer Immunology Immunotherapy · doi:10.1007/bf00199826 · Cited by 44
A tumor-specific Th2 clone initiating tumor rejection via primed CD8+ cytotoxic T-lymphocyte activation in mice.
Shen, Y., & FUJIMOTO, S. (1996) · PubMed · Cited by 38
Requirement of Thymus-Derived θ-Positive Lymphocytes for Rejection of DNA Virus (SV40) Tumors in Mice
Tevethia, S. S., Blasecki, J. W., Waneck, G. L., & Goldstein, A. L. (1974) · The Journal of Immunology · doi:10.4049/jimmunol.113.5.1417 · Cited by 38
Induction of cytotoxic T‐cell response by optimal‐length peptides does not require CD4+ T‐cell help
Fayolle, C., Abdel‐Motal, U. M., Berg, L., Dériaud, E., Jondal, M., & Leclerc, C. (1996) · Immunology · doi:10.1046/j.1365-2567.1996.d01-704.x · Cited by 28
Sequential Involvement of Two Distinct CD4+ Regulatory T Cells during the Course of Transplantable Tumor Growth and Protection from 3–Methylcholanthrene‐induced Tumorigenesis by CD25–depletion
Tawara, I., Take, Y., Uenaka, A., Noguchi, Y., & Nakayama, E. (2002) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2002.tb01337.x · Cited by 26
Phenotype of syngeneic tumor-specific cytotoxic T-lymphocytes and requirements for their in vitro generation from tumor-bearing host and immune spleens.
Bear, H. D., Süßkind, B., Close, K. A., & Barrett, S. K. (1988) · PubMed · Cited by 26
Immunophenotypic markers in renal cell carcinoma.
Banner, B. F., Burnham, J. A., Bahnson, R. R., Ernstoff, M. S., & Auerbach, H. E. (1990) · PubMed · Cited by 26
Changes on Distribution of CD4+/ CD45RA- and CD87CD1Y Cells in Tumor-Infiltrating Lymphocytes of Renal Cell Carcinoma Associated with Tumor Progression
Igarashi, T., Murakami, S., Takahashi, H., Matsuzaki, O., & Shimazaki, J. (1992) · European Urology · doi:10.1159/000474780 · Cited by 21
T-cell responses at the host: tumour interface
Robins, R. A. (1986) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(86)90019-3 · Cited by 19
The Role of Tumor Necrosis Factor and Lymphotoxin in Lymphoid Organ Development
Ettinger, R. (2000) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-57276-0_26 · Cited by 17
Melanoma cell lysis by human CTL clones: Differential involvement of T3, T8 and HLA antigens
Fossati, G., Anichini, A., & Parmiani, G. (1987) · International Journal of Cancer · doi:10.1002/ijc.2910390606 · Cited by 14
Ultraviolet light, tumors, and suppressor T cells
Spellman, C., & Daynes, R. A. (1981) · Human Pathology · doi:10.1016/s0046-8177(81)80139-6 · Cited by 6
Interplay between dietary inducers of GST and theGSTM-1 genotype in colon cancer
Slattery, M. L., Kampman, E., Samowitz, W. S., Caan, B. J., & Potter, J. D. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000901)87:5 · Cited by 2

Research works printed but not linked: 1

Allione, 1994, Cancer Res, 54, 6022

Sorted by citations

The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
Gooden, M. J. M., de Bock, G. H., Leffers, N., Daemen, T., & Nijman, H. W. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.189 · Cited by 1,296
Intratumoral Balance of Regulatory and Cytotoxic T Cells Is Associated With Prognosis of Hepatocellular Carcinoma After Resection
Gao, Q., Qiu, S., Fan, J., Zhou, J., Wang, X., Xiao, Y., Xu, Y., Li, Y., & Tang, Z. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4565 · Cited by 1,134
Increased Regulatory T Cells Correlate With CD8 T-Cell Impairment and Poor Survival in Hepatocellular Carcinoma Patients
Fu, J., Xu, D., Liu, Z., Shi, M., Zhao, P., Fu, B., Zhang, Z., Yang, H., Zhang, H., Zhou, C., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.102 · Cited by 897
Self-citation
Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity
He, Y., Fu, L., Li, Y., Wang, W., Gong, M., Zhang, J., Dong, X., Huang, J., Wang, Q., Mackay, C. R., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.002 · Cited by 729
Self-citation
The tumor microenvironment and its contribution to tumor evolution toward metastasis
Lorusso, G., & Rüegg, C. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0530-8 · Cited by 540

See all 299

Authors: Yu, P., & Fu, Y.-X.
Affiliations: University of Chicago (US)
Corresponding author: Yu, Ping
Fu, Yang-Xin
ORCID: Fu, Yang-Xin
Venue: Laboratory Investigation
Publisher: Elsevier BV
Published: 2006-03
Volume: 86
Issue: 3
Pages: 231-245
ISSN: 0023-6837 (ISSN-L)
DOI: 10.1038/labinvest.3700389
OpenAlex: W2061590134
Cited by: 299
References: 211
Citations by year: 2026: 3 · 2025: 9 · 2024: 14 · 2023: 13 · 2022: 15 · 2021: 20 · 2020: 13 · 2019: 15 · 2018: 8 · 2017: 18 · 2016: 12 · 2015: 14 · 2014: 16 · 2013: 11 · 2012: 17
FWCI: 1.35
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 6160 d)
Locations: Laboratory Investigation (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: tumor-infiltrating lymphocytes, regulatory T cells, CD4+CD25+ T cells, CD8+ T cells, CD4+ T helper cells, antitumor immunity, tumor immunosuppression, prognostic value, cancer immunotherapy
MeSH terms: Humans, Neoplasms, Prognosis, CD4-Positive T-Lymphocytes, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, T-Lymphocytes, Regulatory

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tumor-infiltrating T lymphocytes: friends or foes?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks